Dijon, France-based Movmedix said this clearance marks its first FDA nod, enabling the launch of LARS ACJ in the U.S. LARS ACJ addresses acromioclavicular (ACJ) joint injuries in the shoulder.

The company engineered the implant using a biocompatible polyethylene terephthalate (PET). Its knitted surgical scaffold comes in the form of a band, providing fixation during the healing process following syndesmotic trauma. That could include fixation of ACJ separations due to coracoclavicular ligament disruptions. The platform also includes the LARS screws and dedicated surgical instruments.